Project Grant HT94252310152

This federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) provides $234,889 to the University of Louisville to conduct research on using the epigenetic modifying agent guadecitabine (GDEC) to enhance the immune response against prostate cancer. The key objectives are to determine how GDEC can increase antigen presentation and make prostate cancer cells more vulnerable to T cell-based immunotherapies, and to develop a novel...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...

Federal Project Grant Award Summary Tiba Biotech LLC received a $399,300 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 10, 2025, with completion targeted for August 31, 2026. The award supports the development and preclinical testing of an innovative RNA-based cancer immunotherapy platform that combines enhanced self-amplifying RNA (esRNA) encoding tumor antigens with proprietary spleen-targeting...

Federal Grant Award Summary Duke University received a $2.89 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion scheduled for July 31, 2029. This research project, titled "Understanding and Targeting Epigenetic Regulation of Immune Evasion in Prostate Cancer," will investigate how epigenetic mechanisms—specifically through the TNRC18 protein—regulate immune evasion in...

Grant Summary The National Cancer Institute awarded Cedars-Sinai Medical Center $858,798 through the Cancer Treatment Research program (CFDA 93.395) on August 18, 2025, for a research project examining extracellular vesicle (EV)-enclosed circular RNA (circRNA) interactions in prostate cancer immunobiology. The two-year project, extending through July 31, 2027, will investigate novel mechanisms by which prostate cancer cells suppress immune responses through tumor-associated macrophages (TAMs)....

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...

The National Cancer Institute awarded Yale University a $696,189 Project Grant on April 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research investigating mechanisms of CD8 T cell differentiation in tumor-draining lymph nodes. The research project, extending through March 31, 2031, will deliver scientific discoveries aimed at improving immunotherapy outcomes for lung adenocarcinoma patients who do not currently respond to PD-1/PD-L1 blockade therapies....

This federal Project Grant award of $270,981 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a five-year research program to investigate resistance mechanisms to anti-PD-1/L1 immunotherapy in hepatobiliary cancers. The key objectives are to: Conduct a Phase 2 trial evaluating an anti-TIGIT plus anti-PD-1 antibody combination in hepatobiliary cancers refractory to PD-1 blockade. Characterize immune and molecular features of anti-PD-1/L1 therapy-resistant...

Federal Grant Award Summary Duke University's Office of Research Administration received a $607,157 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. This five-year research initiative addresses the urgent clinical need for new molecular targets to treat neuroendocrine prostate cancer (NEPC), an aggressive and lethal subtype with a five-year survival rate below 20%. The research...